NEVVI Medicare utilization intelligence

← back

KNOX, STACEYMD NPI 1750353447 Clinician

Hematology-Oncology · LINCOLN, NE

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE — medical school, self-reported to CMS
In practice about 25 years since medical school (class of 2001, self-reported to CMS)
Location LINCOLN, NE · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 84 codes billed · 109,692 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
BRYAN MEDICAL CENTER
2026
CANCER PARTNERS OF NEBRASKA PC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2024-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1453 Injection, fosaprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1576 Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
J2469 Injection, palonosetron hcl, 25 mcg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
80053 Blood test, comprehensive group of blood chemicals
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
83615 Lactate dehydrogenase (enzyme) level
Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
J0640 Injection, leucovorin calcium, per 50 mg
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J9190 Injection, fluorouracil, 500 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96372 Injection of drug or substance under skin or into muscle
J1626 Injection, granisetron hydrochloride, 100 mcg
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9045 Injection, carboplatin, 50 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J1200 Injection, diphenhydramine hcl, up to 50 mg
83735 Magnesium level
J3490 Unclassified drugs
71260 Ct scan of chest with contrast
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
74177 Ct scan of abdomen and pelvis with contrast
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
84443 Blood test, thyroid stimulating hormone (tsh)
80048 Blood test, basic group of blood chemicals (calcium, total)
82784 Gammaglobulin (immune system protein) measurement
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
84439 Thyroxine (thyroid chemical), free
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J7030 Infusion, normal saline solution , 1000 cc
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
G0136 Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes
85045 Red blood count, automated test
38222 Biopsy and aspiration of bone marrow sample for diagnosis
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
81002 Urinalysis, manual test
84100 Phosphate level
84550 Uric acid level, blood
96411 Administration of additional new drug or substance into vein using push technique
82378 Carcinoembryonic antigen (cea) protein level
82607 Cyanocobalamin (vitamin b-12) level
86140 Measurement c-reactive protein for detection of infection or inflammation
84153 Psa (prostate specific antigen) measurement, total
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
88184 Flow cytometry technique for dna or cell analysis, first marker
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
G0008 Administration of influenza virus vaccine
96360 Infusion into a vein for hydration, 31-60 minutes
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
90661 Influenza vaccine, trivalent derived from cell cultures
96361 Infusion into a vein for hydration, each additional hour
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96523 Irrigation of implanted venous access drug delivery device
96374 Injection of drug or substance into vein
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7050 Infusion, normal saline solution, 250 cc
70491 Ct scan of soft tissue of neck with contrast
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
82746 Folic acid level, serum

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.